First Real-World Insights into Belimumab Use and Outcomes in Routine Clinical Care of Systemic Lupus Erythematosus in Germany: Results from the OBSErve Germany Study.

Autor: Schwarting A; Department of Rheumatology and Clinical Immunology, University Medical Centre of the Johannes Gutenberg-University Mainz, ACURA Center for Rheumatic Diseases Bad Kreuznach, Mainz, Germany. schwarting@uni-mainz.de., Schroeder JO; Department of Internal Medicine 1, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany., Alexander T; Department of Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany., Schmalzing M; Department of Internal Medicine 2, University Hospital, Würzburg, Germany., Fiehn C; ACURA Center for Rheumatic Diseases, Baden-Baden, Germany., Specker C; Department of Rheumatology and Clinical Immunology, University Hospital, Essen, Germany., Perna A; GF Immuno Inflammation/ID Franchise, GlaxoSmithKline, Brentford, UK., Cholmakow-Bodechtel C; Public Health, Kantar Health, Munich, Germany., Koscielny VB; GF Immuno Inflammation/ID Franchise, GlaxoSmithKline, Brentford, UK., Carnarius H; Medical Department, Immunology and Rare Diseases Business Unit, GlaxoSmithKline, Hamburg, Germany.

Publikováno v: Rheumatology and therapy [Rheumatol Ther] 2016 Dec; Vol. 3 (2), pp. 271-290. Date of Electronic Publication: 2016 Nov 01.